首页|期刊导航|中国当代医药|名老中医虫类药经验方全虫散联合甲钴胺治疗血瘀型腰椎间盘突出症的临床效果

名老中医虫类药经验方全虫散联合甲钴胺治疗血瘀型腰椎间盘突出症的临床效果OA

Clinical efficacy of renowned traditional Chinese medicine practitioner experienced prescription Quanchong Powder combined with Mecobalamin in the treatment of blood stasis type lumbar disc herniation

中文摘要英文摘要

目的 探讨名老中医虫类药经验方全虫散联合甲钴胺治疗血瘀型腰椎间盘突出症的临床效果及其对患者血清炎症因子的影响.方法 选取 2024 年 10 月至 2025 年 7 月上海市嘉定区中医医院骨伤科门诊收治的 80 例血瘀型腰椎间盘突出症患者作为研究对象,按照随机数字表法分为对照组与研究组,每组 40 例,脱落 5 例,最终研究组 38 例,对照组 37 例.对照组采用甲钴胺口服治疗,研究组采用名老中医虫类药经验方全虫散联合甲钴胺口服治疗,30 d 为 1 个疗程,共治疗 1 个疗程.评价两组患者的临床疗效,比较两组患者治疗前后的视觉模拟评分法(VAS)评分、麻木评分、Oswestry 功能评分(ODI)及丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、血尿素氮(BUN)、肌酐(Cr)、C 反应蛋白(CRP)和白细胞介素-8(IL-8).结果 研究组总有效率高于对照组,差异有统计学意义(P<0.05).两组患者治疗前后 ALT、AST、BUN和Cr组间和组内比较,差异无统计学意义(P>0.05).治疗后,两组患者 CRP和 IL-8 均低于本组治疗前,且研究组 CRP 和 IL-8 低于对照组,差异有统计学意义(P<0.05).治疗后,两组患者 VAS评分均低于本组治疗前,麻木评分优于本组治疗前,ODI 评分高于本组治疗前,且研究组VAS 评分低于对照组,麻木评分优于对照组,ODI评分高于对照组,差异有统计学意义(P<0.05).结论 名老中医虫类药经验方全虫散治疗血瘀型腰椎间盘突出症具有显著改善肢体疼痛和麻木的临床功效,服用安全且能降低患者炎症因子水平.

Objective To explore the clinical efficacy of the renowned traditional Chinese medicine practitioner experienced prescription Quanchong Powder combined with Mecobalamin in the treatment of blood stasis type lumbar disc herniation,as well as its impact on the serum inflammatory factors of patients.Methods A total of 80 patients with blood stasis type lumbar disc herniation admitted to the Department of Outpatient of Orthopedics of Shanghai Jiading District Traditional Chinese Medicine Hospital of Shanghai from October 2024 to July 2025 were selected as the research subjects,they were divided into the control group and the study group according to the random number table method,with 40 cases in each group,five cases were lost to follow-up,ultimately,there were 38 cases in the study group,37 cases in the control group.The control group was treated with oral Mecobalamin,while the study group was treated with the renowned traditional Chinese medicine practitioner experienced prescription Quanchong Powder combined with oral Mecobalamin.A total of 30 days constituted one treatment course,and the treatment lasted for one course.The clinical efficacy of the two groups was evaluated,and the visual analogue scale(VAS)scores,numbness scores,Oswestry disability index(ODI),alanine transaminase(ALT),aspartate transaminase(AST),blood urea nitrogen(BUN),creatinine(Cr),C-reactive protein(CRP),and interleukin-8(IL-8)of the two groups before and after treatment were compared.Results The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).There were no statistically significant differences in ALT,AST,BUN and Cr between the two groups before and after treatment(P>0.05).After treatment,the CRP and IL-8 of both groups were lower than those before treatment,and the CRP and IL-8 of the study group were lower than those of the control group,with statistically significant differences(P<0.05).After treat-ment,the VAS scores of both groups were lower than those before treatment,the numbness scores were better than those before treatment,the ODI scores were higher than those before treatment,and the VAS score of the study group was lower than that of the control group,the numbness score was better than that of the control group,and the ODI score was higher than that of the control group,with statistically significant differences(P<0.05).Conclusion The renowned traditional Chi-nese medicine practitioner experienced prescription Quanchong Powder for treating blood stasis type lumbar disc herniation has significant clinical efficacy in improving limb pain and numbness,is safe to take,and can reduce the inflammatory factors levels in patients.

牛锋;高慧;蔡晓辉;安军伟;徐建德;詹红生;石瑛;马勇

上海市嘉定区中医医院骨伤科,上海 201800上海市嘉定区中医医院针灸科,上海 201800上海市嘉定区中医医院骨伤科,上海 201800上海市嘉定区中医医院骨伤科,上海 201800上海市嘉定区中医医院骨伤科,上海 201800上海曙光医院骨伤科,上海 200021上海曙光医院骨伤科,上海 200021江苏省中医院骨伤科,江苏 南京 210004

医药卫生

中医经验方全虫散血瘀型腰椎间盘突出症甲钴胺C反应蛋白白细胞介素-8炎症因子

Traditional Chinese medicine experienced prescription Quanchong PowderBlood stasis typeLumbar disc herniationMecobalamineC-reactive proteinInterleukin-8Inflammatory factor

《中国当代医药》 2026 (15)

106-111,6

上海市嘉定区卫生健康委中医药科研立项项目(2024-KY-ZYY-15)上海市嘉定区卫生健康系统医学重点专科建设项目(ZK2024B07)上海市嘉定区公立医院改革与高质量发展示范项目"疁城杏林"人才培养计划项目(JDLCXLZJ-03).

10.3969/j.issn.1674-4721.2026.15.23

评论